Company Overview and News

135
The Zacks Analyst Blog Highlights: Autohome, Kingdee International Software Group, 58.com and Yanzhou Coal Mining

2018-04-17 zacks
Chicago, IL – April 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Autohome Inc. (ATHM - Free Report) , Kingdee International Software Group Company Limited (KGDEY - Free Report) , 58.com Inc. (WUBA - Free Report) and Yanzhou Coal Mining Company Ltd.
SGC K3GD STLD 1171 YZCHF APO.PRB APO.PRA WUBA ATB BAX MCHP APO NEE.PRI NEE.PRJ 0268 YZC ATHM AMCX NEE.PRC AMAT NEE.PRQ NEE.PRR FSLR NEE

14
4 Stocks to Buy as Chinese Economy Remains Resilient

2018-04-16 zacks
The world’s second-largest economy China has been growing by leaps and bounds for the past one year. Further, the Asian Development Bank stated in a report on Apr 11 that China would keep growing more than 6% in 2018 as well as 2019. The recent shift of focus from manufacturing to services has been pivotal in China’s economic growth story.
YZC 0268 K3GD 1171 YZCHF ATHM WUBA ATB UNF

15
The Zacks Analyst Blog Highlights: Autohome, Kingdee International Software Group, China Petroleum & Chemical, Yanzhou Coal Mining and PetroChina

2018-04-06 zacks
Chicago, IL – April 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Autohome Inc. (ATHM - Free Report) , Kingdee International Software Group Company Ltd. (KGDEY - Free Report) , China Petroleum & Chemical Corp.
LINDW K3GD STLD 1171 YZCHF SNP LHCG LCII CLAC ZBRA LSTR YZC 0268 CVGW SNP ATHM PATK CLACW CLACU SAIC FG LIND

14
China Manufacturing & Services PMI Improve: 5 Great Choices

2018-04-05 zacks
Even as China and the United States gear up for a trade war, China’s economy has been gaining traction. While factory activity touched its highest level since last December, services activity rebounded in March after hitting a four-month low in the prior month. Increase in steel production and removal of winter pollution restrictions contributed to these gains.
YZC 0268 SNP K3GD 1171 YZCHF ATHM SNP VIRT

50
Rio Exits Coal Business With $4 Billion of Deals in a Week - Bloomberg

2018-03-28 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
K3GD RIO BLT RIO 1171 YZCHF BHPBF AAL YZC RTPPF BHP UBS AAUKF RIO RTNTF BBL UBS.PRDCL BHP BHPLF NGLOY ULSGF

0
Shenhua Profit Rises to 5-Year High as China Curbs Boost Coal - Bloomberg

2018-03-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
1898 YACAF YZC K3GD 1171 YZCHF YAL 1088

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...